Evidence map›Paper›PMID 31197435›Full record

Observational studyPsychopharmacology2019

Food craving and consumption evolution in patients starting treatment with clozapine.

Marina Garriga, Andrea Mallorquí, Lourdes Serrano, José Ríos, Manel Salamero, Eduard Parellada, Marta Gómez-Ramiro, Cristina Oliveira, Silvia Amoretti, Eduard Vieta and 2 more

Abstract readObservational Study
PubMed Publisher
In one paragraph

Observational study in Psychopharmacology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 3 pooled it
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 3 syntheses or guidelines pooled it, 14 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Review
  6. Observational
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Marina GarrigaBipolar and Depressive Disorders Unit, Institute of Neuroscience, Hospital Clinic Barcelona, University of Barcelona, Barcelona, Catalonia, Spain. magarriga@clinic.cat.ORCID http://orcid.org/0000-0001-7312-4969
Andrea MallorquíDepartment of Psychiatry, Institute of Neuroscience, Hospital Clinic Barcelona, University of Barcelona, Barcelona, Catalonia, Spain.
Lourdes SerranoDepartment of Psychiatry, Institute of Neuroscience, Hospital Clinic Barcelona, University of Barcelona, Barcelona, Catalonia, Spain.
José RíosMedical Statistics Core Facility, Hospital Clinic Barcelona, Barcelona, Catalonia, Spain.
Manel SalameroDepartment of Psychiatry, Institute of Neuroscience, Hospital Clinic Barcelona, University of Barcelona, Barcelona, Catalonia, Spain.
Eduard ParelladaInstitut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Barcelona, Catalonia, Spain.
Marta Gómez-RamiroBarcelona Clinic Schizophrenia Unit (BCSU), Institute of Neuroscience, Hospital Clinic of Barcelona, University of Barcelona, Barcelona, Catalonia, Spain.
Cristina OliveiraBarcelona Clinic Schizophrenia Unit (BCSU), Institute of Neuroscience, Hospital Clinic of Barcelona, University of Barcelona, Barcelona, Catalonia, Spain.
Silvia AmorettiInstitut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Barcelona, Catalonia, Spain.
Eduard VietaBipolar and Depressive Disorders Unit, Institute of Neuroscience, Hospital Clinic Barcelona, University of Barcelona, Barcelona, Catalonia, Spain.
Miquel BernardoInstitut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Barcelona, Catalonia, Spain.
Clemente García-RizoInstitut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Barcelona, Catalonia, Spain.
Centro de Investigación Biomédica en Red de Salud Mental · ESUniversitat de Barcelona · ESUniversitat Autònoma de Barcelona · ES

Funding

Instituto de Salud Carlos III CM17/00102Instituto de Salud Carlos III PI14/00753
6 · The paper itself

Abstract

backgroundAntipsychotic-induced weight gain has been especially related to clozapine and olanzapine. Underlying mechanisms in relation to food preferences with an increased food craving and consumption of specific nutrients have not been extensively studied in patients with serious mental illness (SMI). We aim to describe specific food preferences (craving) and subsequent food consumption in SMI patients starting clozapine, as well as their possible relation to weight and body mass index (BMI).

methodsAn observational prospective follow-up study (18 weeks) was conducted in a cohort of 34 SMI patients who started clozapine due to resistant-psychotic symptoms. Anthropometric measures, Food Craving Inventory (FCI), and a food consumption frequency questionnaire were evaluated at baseline, weeks 8 and 18 of treatment. Statistical analysis included generalized estimating equations models with adjustment for potential confounding factors.

resultsNo longitudinal changes over time were found across the different food craving scores after 18 weeks of treatment. However, adjusted models according to BMI status showed that the normal weight (NW) group presented an increased score for the "complex carbohydrates/proteins" food cravings (- 0.67; 95% CI [- 1.15, - 0.19]; P = 0.010), while baseline scores for "fast-food fats" cravings were significantly higher in the overweight/obese (OWO) group in comparison with NW patients (NW, 2.05; 95% CI [1.60, 2.49]; OWO, 2.81, 95% CI [2.37, 3.25]; P = 0.016). When considering if food craving could predict weight gain, only increments in "fast-food fats" cravings were associated (β = - 5.35 ± 1.67; 95% CI [- 8.64, - 2.06]; P = 0.001).

conclusionsNo longitudinal differences were found for any of the food craving scores evaluated; however, in the NW group, food craving for "complex carbohydrates/proteins" changed. Thus, changes in "fast-food fats" cravings predicted weight increase in this sample. Interventions targeting food preferences may help to mitigate weight gain in patients starting treatment with clozapine.

Indexed as

AdultAntipsychotic AgentsBody WeightClozapineCohort StudiesCravingEatingFemaleFollow-Up StudiesFood PreferencesHumansLongitudinal StudiesMaleMental DisordersMiddle AgedProspective StudiesAntipsychotic AgentsClozapineAntipsychotic-induced weight gainClozapineFood Craving Inventory (FCI)Serious mental illness

Identifiers

PMID31197435
OpenAlexW2950909263

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.